Table 1 Cohort characteristics
Control | Typical AD | Atypical AD | |
|---|---|---|---|
n = 16 | n = 17 | n = 16 | |
Sex (Female) | 8 (50%) | 4 (23.5%) | 5 (31.2%) |
Age at death (In years) | 71 (± 8) [59–85] | 69 (± 11) [53–89] | 66 (± 10) [37–78] |
Age at Onset (In years) | NA | 61 (± 10) [46–81] | 61 (± 10) [32–74] |
Disease duration (In years) | NA | 8 (± 3) [2–14] | 4 (± 3)^ [1–10] |
Clinical Dementia Rating Scale NA/0/1/2/3 | NA | 6/0/5/2/4 | 2/0/3/2/9 |
Clinical Subtyping NA/Behav/dysex/logo/visuo | NA | NA | 1/3/5/3/4 |
APOE genotyping APOE4 carrier | 4 (26.6%) | 10 (58.8%) | 11 (68.8%)* |
Post-Mortem delay (Hours:minutes) | 8:13 (± 1:51) | 8:12 (± 1:25) | 7:42 (± 1:46) |
MRI | |||
Normalized Whole Brain Volume % ICV | 70.2 (± 4.5) | 60.9 (± 5.6)*** | 61.1 (± 7.7)*** |
Normalized Gray Matter Volume % ICV | 40.2 (± 3.3) | 35.9 (± 3.3)*** | 34.9 (± 5.5)** |
Normalized White Matter Volume % ICV | 30.0 (± 1.9) | 25.0 (± 4.3)*** | 26.2 (± 4.1)** |
Global Cortical Atrophy 0/1/2/3/4 | 13/3/0/0 | 2/10/4/1*** | 5/6/2/3* |
Parietal Cortical Atrophy 0/1/2/3/4 | 10/5/1/0 | 0/9/6/2*** | 1/4/8/3*** |
Medial Temporal Lobe Atrophy 0/1/2/3/4 | 9/6/1/0/0 | 1/5/4/4/3** | 1/5/4/5/1** |
Fazekas 0/1/2/3 | 6/3/7/0 | 6/5/1/5* | 4/3/6/3 |
Pathology | |||
Braak NFT stage 0/1/2/3/4/5/6 | 3/10/3/0/0/0/0/ | 0/0/0/0/3/5/9 *** | 0/0/0/0/1/6/9 *** |
Thal Aβ phase 0/1/2/3/4/5 | 3/7/4/2/0/0 | 0/0/0/1/0/16 *** | 0/0/0/0/2/14 *** |
Braak LB stage 0/1/2/3/4/5/ | 14/2/0/0/0/0/ | 14/0/1/0/1/1/ | 13/0/0/1/0/2 |
LATE stage 0/1/2/3 | 16/0/0/0 | 11/2/3/1 | 13/1/1/1 |
CAA-Type 0/1/2 | 13/1/2 | 1/14/2 *** | 0/10/6 *** |